{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NON-breast+HER2%2B+Malignancies&page=2", "query": { "condition": "NON-breast HER2+ Malignancies", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NON-breast+HER2%2B+Malignancies&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T21:19:38.094Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04143711", "title": "Study of DF1001 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "DF1001", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dragonfly Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 270, "start_date": "2019-11-11", "completion_date": "2025-12-05", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-07-24T21:19:38.094Z", "location_count": 16, "location_summary": "Irvine, California • Los Angeles, California • San Diego, California + 13 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04143711" }, { "nct_id": "NCT02599194", "title": "18F-FSPG PET/CT for Cancer Patients on Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Neoplasm", "Estrogen Receptor Negative", "HER2/Neu Negative", "Metastatic Renal Cell Cancer", "Progesterone Receptor Negative", "Stage III Mesothelioma", "Stage III Renal Cell Cancer", "Stage IIIA Breast Cancer", "Stage IIIA Non-Small Cell Lung Cancer", "Stage IIIB Non-Small Cell Lung Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Mesothelioma", "Stage IV Non-Small Cell Lung Cancer", "Stage IV Renal Cell Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "18F-FSPG", "type": "DRUG" }, { "name": "18F-FDG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Andrei Iagaru", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2015-07", "completion_date": "2016-12-14", "has_results": true, "last_update_posted_date": "2019-01-03", "last_synced_at": "2026-07-24T21:19:38.094Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02599194" }, { "nct_id": "NCT05194072", "title": "A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Neoplasms", "Peritoneal Neoplasms", "Fallopian Tube Neoplasms", "Triple Negative Breast Neoplasms", "HER2 Negative Breast Neoplasms", "Hormone Receptor Positive Breast Neoplasms", "Endometrial Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Cholangiocarcinoma", "Gallbladder Carcinoma", "Adenoid Cystic Carcinoma" ], "interventions": [ { "name": "Felmetatug Vedotin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2022-01-12", "completion_date": "2025-05-14", "has_results": false, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-07-24T21:19:38.094Z", "location_count": 22, "location_summary": "Aurora, Colorado • Denver, Colorado • Celebration, Florida + 9 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05194072" }, { "nct_id": "NCT02411656", "title": "Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Edema", "Erythema", "Estrogen Receptor Negative", "HER2/Neu Negative", "Peau d'Orange", "Progesterone Receptor Negative", "Recurrent Inflammatory Breast Carcinoma", "Stage IV Inflammatory Breast Carcinoma", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2015-06-11", "completion_date": "2028-12-31", "has_results": true, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-07-24T21:19:38.094Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02411656" }, { "nct_id": "NCT05592483", "title": "An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "None (Observational Study)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 78, "start_date": "2023-07-07", "completion_date": "2024-05-29", "has_results": false, "last_update_posted_date": "2024-11-07", "last_synced_at": "2026-07-24T21:19:38.094Z", "location_count": 40, "location_summary": "Mobile, Alabama • Chandler, Arizona • Little Rock, Arkansas + 36 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05592483" }, { "nct_id": "NCT05546268", "title": "Study of Oral MRT-2359 in Selected Cancer Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "NSCLC", "SCLC", "High Grade Neuroendocrine Cancer", "DLBCL", "L-MYC and N-MYC Amplified Solid Tumors", "NSCLC With High or Low L-MYC or N-MYC Expression", "HR-positive, HER2-negative Breast Cancer", "Prostate Cancer" ], "interventions": [ { "name": "Oral MRT-2359", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Monte Rosa Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2022-10-12", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-07-24T21:19:38.094Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 13 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lawrence", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05546268" }, { "nct_id": "NCT03822468", "title": "Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "18 Years to 100 Years · Female only" }, "enrollment_count": 376, "start_date": "2019-06-11", "completion_date": "2024-08-30", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-07-24T21:19:38.094Z", "location_count": 14, "location_summary": "Mobile, Alabama • Greenbrae, California • Longmont, Colorado + 11 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Greenbrae", "state": "California" }, { "city": "Longmont", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03822468" }, { "nct_id": "NCT03872505", "title": "Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-07", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2021-08-25", "last_synced_at": "2026-07-24T21:19:38.094Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03872505" }, { "nct_id": "NCT06784193", "title": "Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)", "Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "Metastatic Breast Cancer", "Fulvestrant", "Palazestrant" ], "interventions": [ { "name": "OP-3136", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Palazestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Olema Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2024-12-16", "completion_date": "2027-08-30", "has_results": false, "last_update_posted_date": "2025-10-10", "last_synced_at": "2026-07-24T21:19:38.094Z", "location_count": 7, "location_summary": "Sarasota, Florida • New Orleans, Louisiana • Boston, Massachusetts + 4 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06784193" }, { "nct_id": "NCT04982926", "title": "A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Glioblastoma", "Non-small Cell Lung Cancer", "Breast Cancer" ], "interventions": [ { "name": "TAS2940", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2021-09-16", "completion_date": "2025-03-24", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-07-24T21:19:38.094Z", "location_count": 2, "location_summary": "Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04982926" } ] }